Arcturus Gross Profit from 2010 to 2024

ARCT Stock

USD 16.91 0.16 0.94%

Arcturus Therapeutics Gross Profit yearly trend continues to be comparatively stable with very little volatility. Gross Profit is likely to outpace its year average in 2024. Gross Profit is the profit Arcturus Therapeutics Holdings makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2016-12-31

Previous Quarter

45.1 M

Current Value

41.7 M

Quarterly Volatility

35.6 M

Covid

Check Arcturus Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Arcturus Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.1 M, Interest Expense of 530 K or Selling General Administrative of 55.5 M, as well as many indicators such as Price To Sales Ratio of 5.06, Dividend Yield of 0.0 or PTB Ratio of 3.17. Arcturus financial statements analysis is a perfect complement when working with Arcturus Therapeutics Valuation or Volatility modules.

Check out the analysis of Arcturus Therapeutics Correlation against competitors.

Latest Arcturus Therapeutics' Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Arcturus Therapeutics Holdings over the last few years. Gross profit is a required income statement account that reflects total revenue of Arcturus Therapeutics Holdings minus its cost of goods sold. It is profit before Arcturus Therapeutics operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Arcturus Therapeutics' Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arcturus Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 62.95 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Arcturus Gross Profit Regression Statistics

	Arithmetic Mean	13,333,370
	Geometric Mean	0.00
	Coefficient Of Variation	566.85
	Mean Deviation	46,237,343
	Median	0.00
	Standard Deviation	75,579,672
	Sample Variance	5712.3T
	Range	322M
	R-Value	0.33
	Mean Square Error	5495.1T
	R-Squared	0.11
	Significance	0.23
	Slope	5,521,292
	Total Sum of Squares	79972T

Arcturus Gross Profit History

	2024	162.5 M
	2023	154.8 M
	2022	62.7 M
	2021	-159.5 M
	2020	-46.4 M
	2019	-11.7 M
	2018	-1.2 M

Other Fundumenentals of Arcturus Therapeutics

Gross Profit Margin

Arcturus Therapeutics Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Net Tangible Assets	Property Plant Equipment	Capital Surpluse	Long Term Investments	Current Deferred Revenue	Short Long Term Debt	Net Invested Capital	Net Working Capital	Long Term Debt	Long Term Debt Total	Capital Stock	Deferred Long Term Liab
Total Assets		0.98	-0.97	-0.91	0.84	0.61	0.92	1.0	-0.24	0.54	0.95	0.77	0.96	-0.63	0.88	0.78	0.96	0.96	0.84	0.84	-0.87	0.57
Total Stockholder Equity	0.98		-0.98	-0.82	0.81	0.56	0.83	0.98	-0.24	0.45	0.98	0.68	0.92	-0.58	0.8	0.69	0.97	0.97	0.74	0.74	-0.81	0.43
Net Debt	-0.97	-0.98		0.79	-0.91	-0.44	-0.84	-0.98	0.25	-0.51	-0.97	-0.6	-0.9	0.6	-0.77	-0.61	-0.99	-0.99	-0.71	-0.71	0.85	-0.42
Retained Earnings	-0.91	-0.82	0.79		-0.68	-0.7	-0.97	-0.89	0.23	-0.59	-0.76	-0.87	-0.92	0.61	-0.96	-0.9	-0.81	-0.79	-0.97	-0.97	0.81	-0.82
Accounts Payable	0.84	0.81	-0.91	-0.68		0.22	0.78	0.85	-0.16	0.51	0.8	0.41	0.72	-0.7	0.64	0.41	0.88	0.88	0.58	0.58	-0.89	0.35
Net Receivables	0.61	0.56	-0.44	-0.7	0.22		0.63	0.58	-0.11	-0.01	0.54	0.85	0.69	-0.41	0.81	0.84	0.42	0.46	0.78	0.78	-0.51	0.62
Total Liab	0.92	0.83	-0.84	-0.97	0.78	0.63		0.91	-0.21	0.67	0.79	0.85	0.92	-0.66	0.93	0.87	0.84	0.82	0.95	0.95	-0.88	0.76
Total Current Assets	1.0	0.98	-0.98	-0.89	0.85	0.58	0.91		-0.24	0.53	0.96	0.74	0.95	-0.64	0.87	0.74	0.97	0.97	0.82	0.82	-0.87	0.54
Common Stock	-0.24	-0.24	0.25	0.23	-0.16	-0.11	-0.21	-0.24		-0.16	-0.32	-0.21	-0.37	-0.34	-0.23	-0.21	-0.29	-0.3	-0.26	-0.26	0.36	-0.17
Short Term Debt	0.54	0.45	-0.51	-0.59	0.51	-0.01	0.67	0.53	-0.16		0.39	0.5	0.5	-0.33	0.41	0.52	0.57	0.47	0.55	0.55	-0.48	0.53
Net Tangible Assets	0.95	0.98	-0.97	-0.76	0.8	0.54	0.79	0.96	-0.32	0.39		0.63	0.93	-0.47	0.78	0.64	0.96	0.97	0.7	0.7	-0.79	0.39
Property Plant Equipment	0.77	0.68	-0.6	-0.87	0.41	0.85	0.85	0.74	-0.21	0.5	0.63		0.82	-0.5	0.86	0.99	0.62	0.6	0.92	0.92	-0.68	0.77
Capital Surpluse	0.96	0.92	-0.9	-0.92	0.72	0.69	0.92	0.95	-0.37	0.5	0.93	0.82		-0.46	0.93	0.84	0.91	0.91	0.9	0.9	-0.82	0.66
Long Term Investments	-0.63	-0.58	0.6	0.61	-0.7	-0.41	-0.66	-0.64	-0.34	-0.33	-0.47	-0.5	-0.46		-0.57	-0.47	-0.56	-0.56	-0.53	-0.53	0.67	-0.36
Current Deferred Revenue	0.88	0.8	-0.77	-0.96	0.64	0.81	0.93	0.87	-0.23	0.41	0.78	0.86	0.93	-0.57		0.89	0.76	0.77	0.97	0.97	-0.79	0.78
Short Long Term Debt	0.78	0.69	-0.61	-0.9	0.41	0.84	0.87	0.74	-0.21	0.52	0.64	0.99	0.84	-0.47	0.89		0.63	0.61	0.95	0.95	-0.66	0.81
Net Invested Capital	0.96	0.97	-0.99	-0.81	0.88	0.42	0.84	0.97	-0.29	0.57	0.96	0.62	0.91	-0.56	0.76	0.63		0.99	0.72	0.72	-0.83	0.47
Net Working Capital	0.96	0.97	-0.99	-0.79	0.88	0.46	0.82	0.97	-0.3	0.47	0.97	0.6	0.91	-0.56	0.77	0.61	0.99		0.7	0.7	-0.83	0.46
Long Term Debt	0.84	0.74	-0.71	-0.97	0.58	0.78	0.95	0.82	-0.26	0.55	0.7	0.92	0.9	-0.53	0.97	0.95	0.72	0.7		1.0	-0.77	0.85
Long Term Debt Total	0.84	0.74	-0.71	-0.97	0.58	0.78	0.95	0.82	-0.26	0.55	0.7	0.92	0.9	-0.53	0.97	0.95	0.72	0.7	1.0		-0.77	0.85
Capital Stock	-0.87	-0.81	0.85	0.81	-0.89	-0.51	-0.88	-0.87	0.36	-0.48	-0.79	-0.68	-0.82	0.67	-0.79	-0.66	-0.83	-0.83	-0.77	-0.77		-0.53
Deferred Long Term Liab	0.57	0.43	-0.42	-0.82	0.35	0.62	0.76	0.54	-0.17	0.53	0.39	0.77	0.66	-0.36	0.78	0.81	0.47	0.46	0.85	0.85	-0.53

Click cells to compare fundamentals

About Arcturus Therapeutics Financial Statements

Arcturus Therapeutics shareholders use historical fundamental indicators, such as Gross Profit, to determine how well the company is positioned to perform in the future. Although Arcturus Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Arcturus Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Arcturus Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

	Last Reported	Projected for Next Year
Gross Profit	154.8 M	162.5 M
Gross Profit Margin	0.98	1.03

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Arcturus Stock Analysis

When running Arcturus Therapeutics' price analysis, check to measure Arcturus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arcturus Therapeutics is operating at the current time. Most of Arcturus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Arcturus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arcturus Therapeutics' price. Additionally, you may evaluate how the addition of Arcturus Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC